Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Charles River Laboratories International, Inc. (NYSE:CRL) has earned a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $208.50.

Several equities research analysts have recently issued reports on the company. Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a research report on Friday, May 8th. Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price for the company. Evercore reaffirmed an “outperform” rating and set a $220.00 target price on shares of Charles River Laboratories International in a research report on Friday, May 8th. Finally, TD Cowen decreased their target price on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, February 20th.

Institutional Investors Weigh In On Charles River Laboratories International

Large investors have recently made changes to their positions in the business. Invesco Ltd. increased its holdings in Charles River Laboratories International by 115.8% in the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after acquiring an additional 1,446,972 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in Charles River Laboratories International in the 4th quarter worth about $176,478,000. Victory Capital Management Inc. increased its holdings in Charles River Laboratories International by 9,938.8% in the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after acquiring an additional 684,586 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Charles River Laboratories International by 1,491.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after acquiring an additional 575,039 shares during the last quarter. Finally, National Bank of Canada FI increased its holdings in Charles River Laboratories International by 117.7% in the 3rd quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after acquiring an additional 511,901 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Up 3.0%

NYSE CRL opened at $180.10 on Thursday. The firm has a market capitalization of $8.68 billion, a P/E ratio of -47.90, a PEG ratio of 2.00 and a beta of 1.46. The business has a fifty day simple moving average of $170.53 and a 200 day simple moving average of $181.44. Charles River Laboratories International has a 12 month low of $138.81 and a 12 month high of $228.88. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. During the same period in the prior year, the firm posted $2.34 EPS. Charles River Laboratories International’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts predict that Charles River Laboratories International will post 11.04 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.